Sevabertinib clinical trials
Also written BAY2927088.
How each study uses sevabertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sevabertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Nov 2025 · HYRNUO · NDA 219972 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test sevabertinib, phase 3 first.
Studies
Open first, then newest update. How each study uses sevabertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingPhase 2BayerNCT06760819Written as BAY2927088
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingPhase 3BayerNCT06452277Written as Sevabertinib
- Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the BodyCompletedPhase 1BayerNCT07753252Written as Sevabertinib (BAY 2927088)
- A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral DoseCompletedPhase 1BayerNCT07102095Written as Sevabertinib
- A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy ParticipantsCompletedPhase 1BayerNCT06378658Written as BAY2927088
- A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy ParticipantsCompletedPhase 1BayerNCT06329895Written as BAY2927088
- A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy ParticipantsCompletedPhase 1BayerNCT06360211Written as BAY2927088
- A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male ParticipantsCompletedPhase 1BayerNCT06221475Written as BAY2927088 coated tablet 10 mg
Given beside what is tested · 1 — sevabertinib is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the BodyOct 22, 2026NCT07753252
Codes
What other systems call sevabertinib · ClinicalTrials.gg INT002180
- MeSH (NLM) C000731961sevabertinibOne source NLM
- UNII (FDA) 2A7VPM5RWHSEVABERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q137258574sevabertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C185187SevabertinibOne source FDA
- DrugBank DB21667One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731961 | sevabertinib | One source NLM |
| UNII (FDA) | 2A7VPM5RWH | SEVABERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q137258574 | sevabertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C185187 | Sevabertinib | One source FDA |
| DrugBank | DB21667 | — | One source Wikidata |
Also registered as sevabertinib hydrate (UNII R3MU6CA5SZ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.